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In recent Correspondence about the screening and treatment of latent tuberculosis infection in migrants 
who had moved from countries with a high tuberculosis burden to low-burden countries, Kayvan 
Bozorgmehr1 reported that asylum seekers in Germany from Somalia and Iraq had very different 
prevalences of latent infection. He commented that “Many studies on effectiveness of tuberculosis 
screening treat migrants as homogenous, neglecting that this population is socially constructed and highly 
heterogeneous”, citing our study2 as one of the examples. 
In fact, we did not treat our study cohort as homogeneous: we presented analysis considering age, sex, visa 
category (students, settlement and dependants, work, working holiday, family reunion, other), and 
tuberculosis prevalence of the country of origin, and found that there were significant differences in 
tuberculosis risk associated with the last two variables.2 This complements earlier work on the yield of 
latent tuberculosis infection screening in England,3,4 which informed the new national screening 
programme in England. 
We agree with Bozorgmehr that collection of detailed data is important “to develop and assess screening 
programmes that account for the heterogeneity in migrant populations”.1 We would like to highlight that in 
addition to latent tuberculosis infection prevalence in different migrant groups, several other important 
considerations are related to the effectiveness, cost-effectiveness, and equity3–5 of tuberculosis control 
programmes for migrants. Addressing them requires detailed data from programmes,6 including data 
linkage between pre-entry screening programmes,7 post-migration latent tuberculosis infection screening 
and treatment programmes, and surveillance of active tuberculosis diagnoses. 
Programmes need to ensure access to screening, promote treatment uptake in patients with diagnosed 
latent tuberculosis infection, and provide effective support for adherence to treatment, in ways that are 
culturally sensitive and cost-effective. 
Uncertainty in the effectiveness of latent tuberculosis infection treatment regimens8 causes uncertainty in 
the expected impact and cost-effectiveness of screening and treatment programmes. Record linkage of 
large, detailed datasets from such screening programmes and surveillance of active tuberculosis diagnoses 
will be essential for assessing and optimising the impact of the programmes. Finally, it is important to 
monitor the epidemiology of tuberculosis and the performance of control programmes at the local level to 
ensure appropriate allocation of resources and equitable access to care.5 
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